Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 – Clinical Trials Optional)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for researchers investigating disparities in liver diseases and liver cancer. Eligible applicants include academic institutions, research hospitals, nonprofits, and other organizations with research capacity. The focus is on clinical research addressing health inequities. Applicants must have IRB approval for human subjects research and institutional infrastructure to conduct rigorous studies. Domestic and some international institutions may apply; check NIH guidelines for specific institutional eligibility.
Not the right fit? Find grants for your organization in 5 questions →
Program description
This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.). This NOFO is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Hospital
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Required documents
- NIH Form SF-424
- Research Plan (Specific Aims, Significance, Innovation, Approach)
- Institutional biosketches for key personnel
- Budget and budget justification
- IRB approval letter or certification
- Letters of institutional commitment
- Protection of Human Subjects documentation (if applicable)
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.273 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$125,900,663
-
$34,675,742
-
$34,469,501
-
$33,261,336
-
$32,897,567
-
$31,652,514
-
$30,394,602
-
$29,223,384
-
$29,195,978
-
$29,168,993
Top States by Funding
- CA 15 awards $242.3M
- NY 3 awards $162.6M
- OR 7 awards $96.3M
- NC 4 awards $67.1M
- IN 3 awards $57.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.273). How funding has trended year over year.
| 2024 | $430,377,419 | |
| 2025 | $429,906,735 | |
| 2026 est. | $12,401,560 |
FAQ
Who can apply for this grant?
Domestic and eligible foreign institutions with research capacity can apply. This includes universities, hospitals, nonprofits, and government agencies. Your institution must have NIH research infrastructure.
What research topics are fundable?
Research addressing disparities in liver diseases and liver cancer. Studies examining barriers to care, prevention, diagnosis, and treatment are encouraged. Health equity is central to the program.
What is the typical funding amount?
R01 grants typically provide $150,000–$250,000 annually for direct costs. Funding levels depend on project scope and reviewer assessment.
Is clinical trials experience required?
No. This mechanism is "clinical trials optional," so basic research is fundable. However, human subjects research requires full IRB approval.
When is the application due?
The deadline is January 7, 2028. Allow significant time for institutional approvals and internal review.
💡 Tips for applicants
- Emphasize health disparities and equity in your research questions. Use strong data on disparate outcomes among specific populations.
- Design rigorous, feasible studies. Reviewers evaluate scientific rigor and realistic timelines carefully.
- Include letters of support from collaborators and clinical partners. Multi-institutional teams strengthen applications.
- Address health equity explicitly in your aims and methods. Don't treat disparities as a secondary consideration.
- Build in explicit plans for recruitment and retention of underrepresented populations if human subjects are involved.
⚠️ Common mistakes
Weak rationale for why disparities exist in your population. Failing to address equity in study design and analysis. Underestimating time and budget for rigorous clinical research with diverse populations.
Similar grants
- OPEN Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional) — National Institutes of Health
- CLOSED Forecast to Publish a Notice of Funding Opportunity Announcement for Addressing Determinants of Health Disparities Among Rural Populations (R01 – Clinical Trial Optional) — National Institutes of Health
- OPEN Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) — National Institutes of Health